DEA schedules Epidiolex, allowing GW Pharma to start selling the drug

The Drug Enforcement Administration has rescheduled Epidiolex, paving the way GW Pharmaceuticals to start selling the first FDA-approved drug that’s derived from cannabis, but stopping short of resclassifying all cannabidiol products.

Source link

Leave a Comment

Aetna, seeking antitrust nod, sells Medicare drug business to WellCareNHS dental patients 'face 90-mile trip', union claims